ArticleCell reports2022
The lactate-NAD
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 65 citations in OpenAlex.
- Review
- The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy.Clinical and translational medicine · 2026Review
- Lactate and lactylation in hepatocellular carcinoma: A new frontier in metabolic-epigenetic interactions.Medical oncology (Northwood, London, England) · 2026Review
- Hypoxia/lactate orchestrates the reprogramming metabolism of lung adenocarcinoma by modulating the SIRT2-mediated acetylation.Journal of translational medicine · 2026Article
- Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression.Nature communications · 2026Article
- Mechanisms of actin-binding proteins in glycolysis-cytoskeleton coupling.Journal of translational medicine · 2026Review
- SHH drives gastric cancer-associated fibroblast activation via ACLY-dependent acetyl-CoA metabolism and histone acetylation.Discover oncology · 2026Article
- Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Molecular vehicles for therapeutic delivery of lactate in exercise and medicine.Sports medicine and health science · 2026Review
- Immune cross talk and therapeutic advances in lactate metabolism in the tumor microenvironment (Review).Experimental and therapeutic medicine · 2026Review
- Glycolysis enzymes and cellular lactylation in tumour.Clinical and translational medicine · 2026Review
- Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Lactate, a Spearhead of Cancer Aggressiveness: Metabolic Reprogramming, Immune Suppression, and Metastatic Progression.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026Review
- The microbiota-host metabolic axis in cervical cancer: from homeostatic disruption to mechanisms of therapy resistance.Frontiers in cellular and infection microbiology · 2026Review
- Tumor-stromal metabolic crosstalk in pancreatic cancer.Trends in cell biology · 2025Review
- Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by enhancing nucleotide excision repair in bladder cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Crosstalk between cancer‑associated fibroblasts and inflammation in tumor microenvironment: A novel perspective in cancer therapy (Review).Oncology reports · 2025Review
- Lactate-Mediated Crosstalk Between Tumor Cells and Cancer-Associated Fibroblasts: Mechanisms and Therapeutic Opportunities.International journal of molecular sciences · 2025Review
- Burning lactic acid: a road to revitalizing antitumor immunity.Frontiers of medicine · 2025Review
- Tumor Microenvironment Lactate: Is It a Cancer Progression Marker, Immunosuppressant, and Therapeutic Target?Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Juan F LinaresDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Tania Cid-DiazDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Angeles DuranDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Marta OsrodekDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Anxo Martinez-OrdoñezDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Miguel Reina-CamposSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Hui-Hsuan KuoEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Olivier ElementoEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
M Laura MartinEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Thekla CordesDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA.
Timothy C ThompsonDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christian M MetalloDepartment of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA; Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Jorge MoscatDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: jom4010@med.cornell.edu.
Maria T Diaz-MecoDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: mtd4001@med.cornell.edu.
Cornell University · USWeill Cornell Medicine · USUniversity of California, San Diego · USDiscovery Institute · USThe University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2MViral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Reuben Shaw · 1985 to 2026
$82.8MWeill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LODA, MASSIMO · 2017 to 2021
$10.9MRole of p62 in metabolic reprograming of the tumor stroma in prostate cancerR01CA218254 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DIAZ MECO CONDE, MARIA TERESA, METALLO, CHRISTIAN MICHAEL · 2017 to 2021
$2.6MInterferon regulation by NBR1-driven chaperone-mediated autophagy in stellate cells in liver cancerR01CA265892 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jorge Moscat · 2022 to 2026
$2.4MMolecular mechanisms driving mesenchymal colorectal cancerR01CA250025 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCAT, JORGE · 2021 to 2025
$2.2MNovel Pathways in the Control of Lineage Plasticity in Neuroendocrine Prostate CancerR01CA246765 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DIAZ MECO CONDE, MARIA TERESA · 2020 to 2024
$2.1MNon-essential amino acids and sphingolipid diversity in cancer progressionR01CA234245 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI METALLO, CHRISTIAN MICHAEL · 2019 to 2023
$1.9MIdentifying and exploiting metabolic vulnerabilities in cancer using mass spectrometry and tracing approachesR50CA252146 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CORDES, THEKLA · 2021 to 2021
$168kNCI NIH HHS P30 CA014195NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA030199NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA218254NCI NIH HHS R01 CA234245NCI NIH HHS R01 CA246765NCI NIH HHS R01 CA250025NCI NIH HHS R01 CA265892NCI NIH HHS R50 CA252146
Abstract
Reduced p62 levels are associated with the induction of the cancer-associated fibroblast (CAF) phenotype, which promotes tumorigenesis in vitro and in vivo through inflammation and metabolic reprogramming. However, how p62 is downregulated in the stroma fibroblasts by tumor cells to drive CAF activation is an unresolved central issue in the field. Here we show that tumor-secreted lactate downregulates p62 transcriptionally through a mechanism involving reduction of the NAD
Indexed as
Cancer-Associated FibroblastsNeoplasmsFibroblastsLactic AcidNADPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesLactic AcidNADPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesAP-1cancer-associated fibroblastscancer metabolismCP: CancerNAD(+)/NADHolaparibp62PARP inhibitorspoly(ADP-ribose)-polymerase 1SQSTM1stroma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.